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Purpose: Diagnosing corticobasal degeneration (CBD) and progressive supranuclear palsy (PSP) is often difﬁcult
due to the wide variety of symptoms and overlaps in the similar clinical courses and neurological ﬁndings. The
purpose of this study was to evaluate the utility of white matter (WM) atrophy for the diagnosis of patients
with clinically diagnosed CBD (corticobasal syndrome, CBS) and PSP (Richardson’s syndrome, RS).
Methods:We randomly divided the 3D T1-weighted MR images of 18 CBS patients, 33 RS patients, and 32 age-
matched controls into two groups. We obtained segmented WM images in the ﬁrst group using Voxel-based
speciﬁc regional analysis system for Alzheimer’s disease (VSRAD) based on statistical parametric mapping
(SPM) 8 plus diffeomorphic anatomical registration through exponentiated Lie algebra. A target volume of
interest (VOI) for disease-speciﬁc atrophy was subsequently determined in this group using SPM8 group
analyses of WM atrophy between patients groups and controls. We then evaluated the utility of these VOIs for
diagnosing CBS and RS patients in the second group. Z score values in these VOIs were used as the determinant
in receiver operating characteristic (ROC) analyses.
Results: Speciﬁc target VOIs were determined in the bilateral frontal subcortical WM for CBS and in the midbrain
tegmentum for RS. In ROC analyses, the target VOIs of CBS and RS compared to those of controls exhibited
an area under curve (AUC) of 0.99 and 0.84, respectively, which indicated an adequate diagnostic power.
The VOI of CBS revealed a higher AUC than that of RS for differentiating between CBS and RS (AUC, 0.75
vs 0.53).
Conclusions: Bilateral frontal WM volume reduction demonstrated a higher power for differentiating CBS
from RS. This VOI analysis is useful for clinically diagnosing CBS and RS.© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-SA license
(http://creativecommons.org/licenses/by-nc-sa/3.0/).1. Introduction
Corticobasal degeneration (CBD) is a slowly progressive neu-
rodegenerative disorder characterized by tau pathology and distinc-
tive clinical manifestations including asymmetric akinetic-rigid
syndrome and higher cortical dysfunctions such as ideomotor apraxia,
cortical sensor loss, and alien limb (Lang, et al., 1994; Litvan et al.,
2003; Boeve et al., 2003). Clinical features related to dysfunctionst of Diagnostic Radiology, Tokyo
o, Itabashi-ku, Tokyo 173-0015,
. This is an open access article underin the basal ganglia are also present in patients with progressive
supranuclear palsy (PSP), but are generally symmetric and associated
with impairment of infratentorial structures (vertical gaze palsy and
early falls) (Litvan et al., 1996). Apart from such differences in clinical
presentation, an overlap in symptoms has been reported between
CBD and PSP, which makes a differential diagnosis between these neu-
rodegenerative disorders challenging (Boeve et al., 2003; Scaravilli
et al., 2005). Moreover, the classic neuropathology of CBD is found in
patients who presented with progressive aphasia or frontotemporal
dementia, making it difﬁcult to maintain the term CBD as a uniﬁed
clinicopathological entity. The evidence of this poor clinicopathological
correlation has led to the use of the term corticobasal syndrome (CBS)
in clinically diagnosed CBD cases (Kertesz et al., 2000).the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
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resonance imaging (MRI) studies have reported distinct neuroimaging
ﬁndings of clinically or pathologically diagnosed CBD (CBS/CBD),
including asymmetric atrophy in the cerebral cortex and peduncle
with dominance contralateral to the more clinically affected side,
atrophy of the midbrain tegmentum and corpus callosum, and
abnormal T2 prolongation in the subcortical white matter (WM)
(Yamauchi et al., 1998; Tokumaru et al., 2009; Koyama et al., 2007).
Nevertheless, the diagnostic accuracy ofMRI abnormalities is suboptimal
for clinically diagnosed PSP (sensitivity averaging approximately 70%
across different studies) and poor for CBD (Schrag et al., 2000; Yekhlef
et al., 2003; Righini et al., 2004; Gröschel et al., 2006; Josephs et al.,
2004). These disorders can also have similar structural abnormalities
including atrophy of the midbrain tegmentum and asymmetric atrophy
of the cerebral cortex (Tokumaru et al., 2009; Koyama et al., 2007;
Boeve et al., 1999).
Voxel-based morphometry (VBM), which can objectively assess the
whole brain structure with voxel-by-voxel comparisons, has been de-
veloped to analyze tissue volumes between subject groups to distin-
guish degenerative diseases with Parkinsonism. Previous VBM studies
comparing cerebral atrophy between CBS/CBD and PSP patients con-
ﬁrmed more asymmetric dorsal frontal and parietal gray matter (GM)
atrophy in CBS/CBD, and more midbrain tegmental atrophy in PSP
(Boxer et al., 2006; Josephs et al., 2008). In addition to these ﬁndings,
subcortical frontal WM atrophy, which may reﬂect primary degenera-
tion due to tauopathy, has been reported using mainly the SPM 2
and 5 (Boxer et al., 2006; Josephs et al., 2008). However, data on
the utility of WM atrophy for differentiating between clinically diag-
nosed CBD and PSP using the SPM8 plus diffeomorphic anatomical
registration through exponentiated Lie algebra (DARTEL) (Wellcome
Trust Centre for Neuroimaging, London, UK) method (Ashburner,
2007), which can improve registration and provide the precise location
of structural damage in both GM and WM, are scant. The aim of this
study was to compare the utility of structural WM atrophy evaluated
using SPM8 plus DARTEL for differentiating between patients with
a clinical diagnosis of CBD—reported here as CBS—and patients with
the classic clinical phenotype of PSP—reported here as Richardson’s
syndrome (RS).
2. Materials and methods
2.1. Patients and control subjects
The aim of this study was to evaluate the characteristicWM atrophy
of CBS and RS using data retrospectively collected at a single medical
center. This study was approved by the Ethics Committee for Clinical
Research of the Tokyo Metropolitan Medical Center of Gerontology,
which waived the requirement for informed consent. The privacy
of the patients was completely protected. In this retrospective
study, the study groupwas selected following a search of themedical
records ﬁled at the Tokyo Metropolitan Medical Center of Gerontol-
ogy between March 2007 and March 2013. Patient backgrounds
were standardized by applying the following inclusion criteria:
(1) clinical diagnoses according to the published criteria of CBS and
PSP (Lang et al., 1994; Litvan et al., 1996), and (2) acquisition of 3D
T1-weighted SPGR images. An exclusion criterion was the insufﬁcient
quality of 3D T1-weighted SPGR images due to signiﬁcant abnormal
ﬁndings (e.g., large cerebral infarctions) and apparent artifacts which
disturb the VBM analyses. During this period, a total of 59 patients
were suspected to have CBS or PSP. Of these, eight patientswere exclud-
ed due to insufﬁcient MRI qualities. Eighteen CBS (mean age, 79 ±
5 years; 3 men and 15 women) and 33 RS (4 possible and 29 probable)
(mean age, 78 ± 5 years; 20 men and 13 women) patients were ﬁnally
enrolled in this study. Patient characteristics were summarized in
Table 1. Thirty-two age-matched people (mean age, 79 ± 3 years; 19
men and 13women)without obvious neurological orMR abnormalitieswere selected from the normal database of the volunteer subjects at our
institution, and were investigated as control subjects.
2.2. MRI protocol
All 83 patients underwent MRI examinations on a 1.5-T imager
(Signa Excite HD; GE Medical systems, Milwaukee, WI, USA) with a
multichannel head coil. 3D sections of T1-weighted spoiled gradient
recalled echo sequence (SPGR) were mainly obtained in a sagittal
plane, for which the scanning parameters were as follows: repetition
time 21 ms; echo time 6 ms; ﬂip angle 20°; ﬁeld of view 230 mm; ma-
trix, 256 × 192 (i.e., in-plane resolution 0.90 × 1.20 mm); and 1.8-mm
thick gapless sections. 3D SPGR of four CBS patients were obtained in
the axial plane with the same in-plane resolution. All volumetric T1-
weighted images were visually inspected for apparent artifacts due to
patient motion or metallic dental prostheses.
2.3. Image analysis
Using the software program, VSRAD based on SPM8 plus DARTEL
(Matsuda et al., 2012), SPGR images of all subjects were classiﬁed into
GM, WM, and cerebrospinal ﬂuid images using a uniﬁed tissue-
segmentation procedure after image-intensity nonuniformity correc-
tion, anatomically standardized to a customized template of WM
using DARTEL, and were then smoothed using an 8-mm full width
at half maximum isotropic Gaussian kernel. VSRAD provided statisti-
cal Z score images for WM atrophy in each of the patients relative
to that of the “normal” database of WM (Nakatsuka et al., 2013).
The Z score was deﬁned as: ([control mean] − [individual value]) /
(control SD).
In order to conﬁrm the diagnostic accuracy (Nakatsuka et al., 2013),
we divided 18 patients with CBS, 33 patients with RS, and 32 controls
into two groups at random; Group A consisted of 9 CBS patients, 17 RS
patients, and 16 controls, and Group B consisted of 9 CBS patients, 16
RS patients, and 16 controls. The WM reduction pattern of CBS and RS
patients compared to the others in group A was then assessed by seg-
mented WM images on SPM8 full-factorial analysis. The statistical
threshold was set at p b 0.001 uncorrected for multiple comparisons
with an extent threshold of 300 voxels. Age and sex were included in
the model as covariates.
The target volumes of interest (VOI) speciﬁc for CBS andRSwere then
determined using the results of group A analyses. We evaluated the use-
fulness of these target VOIs for diagnosing the remaining 9 CBS patients
and 16 RS patients in group B.We obtained averaged positive Z scores in
the target VOIs with MRIcron (http://www.mccauslandcenter.sc.edu/
mricro/mricron/). Using these averaged positive Z scores in the target
VOI as a threshold,we used IBMSPSS statistics 21 (IBMSPSS Inc, Chicago,
IL, USA) to determine receiver operating characteristic (ROC) curves for
discriminating CBS and RS patients.
2.4. Statistical analysis
Statistical analysis was carried out using IBM SPSS statistics 21.
A one-way ANOVA, the Kruskal–Wallis test, the unpaired t test,
Chi-square test and the Mann–Whitney U test were used to assess
differences in patient characteristics between the groups. Pearson
product-moment and Spearman’s rank correlation coefﬁcient were
used to assess the correlation between the degree of WM atrophy
and clinical parameters including the disease duration and Hoehn-Yahr
stage at time of MRI scan. Differences were considered signiﬁcant when
p b 0.05.
3. Results
Patient characteristics have been summarized in Table 1. No signiﬁ-
cant difference was observed in age among the CBS, RS, and control
Fig. 1. Regions of WM reduction identiﬁed on full-factorial analysis among CBS pa-
tients, RS patients, and controls. Widespread patterns of WM reduction are mainly
identiﬁed in the bilateral frontal and limbic subcortical WM and midbrain. The most
signiﬁcant areas of atrophy within the frontal and limbic lobes include the left anterior
cingulate and right medial frontal gyrus. The SPM of the f statistics is displayed in
a standard format as a maximum intensity projection viewed from the right-hand side
(left image), the back (middle image), and the top (right image) of the brain.
Table 1
Patient and control characteristics.
CBS (n = 18) RS (n = 33) Control (n = 32) p value
Age at the time of MRI (y) 79 ± 5 78 ± 6 79 ± 3 0.67 ⁎
Age at symptom onset (y) 74 ± 5 74 ± 5 NA 0.43 ⁎⁎
Male/Female 3/15 20/13 19/13 0.005 ⁎⁎⁎
Disease duration at time of MRI (y) 4.6 ± 2.3 (1-9) 4.8 ± 2.6 (1-10) NA 0.79 ⁎⁎
Neurological examination ﬁndings at the time of MRI
Asymmetry 18 (100%) 4 (12%) NA b0.001 ⁎⁎⁎⁎
Tremor 6 (33%) 8 (24%) NA 0.49 ⁎⁎⁎⁎
Rigidity 18 (100%) 32 (97%) NA 0.46 ⁎⁎⁎⁎
Limb apraxia 14 (78%) 1 (3%) NA b0.001 ⁎⁎⁎⁎
Apraxia of speech 12 (67%) 2 (6%) NA b0.001 ⁎⁎⁎⁎
Alien limb 2 (13%) a 1 (3%) NA 0.19 ⁎⁎⁎⁎
Myoclonus 4 (25%) a 0 (0%) NA 0.003 ⁎⁎⁎⁎
vertical gaze limitation 5 (28%) 25 (76%) NA b0.001 ⁎⁎⁎⁎
Falls 9 (64%) b 33 (100%) NA b0.001 ⁎⁎⁎⁎
L-dopa beneﬁt (subjective) 0 (0%) 7 (21%) NA 0.04 ⁎⁎⁎⁎
Yahr stage 3.8 ± 1.0 3.9 ± 0.9 NA 0.68 ⁎⁎⁎⁎⁎
1 0 1 NA
2 0 2 NA
2.5 3 2 NA
3 2 6 NA
4 8 14 NA
5 5 8 NA
Data are shown as absolute numbers or the mean ± standard deviation
Note− CBS = corticobasal syndrome, NA = not applicable, RS = Richardson’s syndrome, y = years
* One-way ANOVA
** The unpaired t test
*** Kruskal–Wallis test
**** Chi-square test
***** Mann–Whitney U test
a There were no relevant data in the medical records of two CBS patients
b There were no relevant data in the medical records of four CBS patients
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and Yahr scale between the CBS and RS groups. The number of
women was markedly higher than that of men in the CBS group;
however, this was not observed in the RS or control groups. In the
18 CBS patients, symptoms were right dominant in 12 and left dom-
inant in six.
On full-factorial analysis, widespread patterns of WM reduction
were mainly identiﬁed in the bilateral frontal and limbic subcortical
WM and midbrain (Fig. 1). Patterns of WM reduction in each of the
CBS and RS groups compared to the others are shown in Table 2. The
most signiﬁcant areas of atrophy observed in CBS patients compared
to the controls were the bilateral frontal subcortical WM including the
left precentral gyrus (Fig. 2A, Table 2). The most signiﬁcant areas of at-
rophy observed in RS patients compared to the controls were in the
midbrain (Fig. 2B, Table 2). Additionally, the atrophy of the corpus
callosum in the CBS groups, and subcortical frontal WM in the PSP
groupswere observed at amore lenient threshold of P b 0.05.More atro-
phic lesionswere found in CBS patients than in RS patients, especially in
the bilateral cingulate and right postcentral gyrus (Fig. 3A, Table 2). On
the other hand, signiﬁcant atrophy was identiﬁed in the bilateral
midbrain in RS patients (Fig. 3B, Table 2).
The target VOIs of CBS- and RS-speciﬁc atrophy were determined
from the results of VBM analyses (Fig. 4A, B). ROC analyses using the
averaged positive Z scores of CBS, RS, and control subjects were per-
formed to evaluate the diagnostic accuracy of disease-speciﬁc VOIs
(Fig. 5A–D). A target VOI of CBS including the bilateral frontal
subcortical WM exhibited an area under curve (AUC) of 0.99, sensi-
tivity of 89%, speciﬁcity of 100%, and accuracy of 96% with a cutoff
Z-score of 1.30 (Fig. 5A). A target VOI of RS including the midbrain
exhibited an AUC of 0.84, sensitivity of 81%, speciﬁcity of 81%, and
accuracy of 81% with a cutoff Z-score of 0.97 (Fig. 5B). These results
indicated the adequate discrimination power of disease-speciﬁc
VOIs to differentiate CBS and RS patients from normal controls. Onthe other hand, a comparison of the averaged positive Z scores to dif-
ferentiate CBS from RS patients revealed the higher discrimination
power of CBS-speciﬁc VOI than that of RS-speciﬁc VOI (AUC of 0.75
for CBS-speciﬁc VOI vs AUC of 0.53 for RS-speciﬁc VOI) (Fig. 5C, D).
These results indicated that CBS-speciﬁc VOI in the bilateral frontal
WM could diagnose 89% of CBS patients and exclude 63% of RS
patients from the patient group (i.e., sensitivity 89%, speciﬁcity 63%
with a cutoff Z-score of 1.37). Although RS-speciﬁc VOI in the
midbrain diagnosed 88% of PSP patients, this VOI could not exclude
56% of CBS patients (i.e., sensitivity 88%, speciﬁcity 44% with a cutoff
Z-score of 0.83).
CBS patients revealed a moderately positive correlation between
WM atrophy (i.e., Z-score in the VOI) and Hoehn-Yahr stage (r = 0.5,
P=0.035). On the other hand, this correlation was weak in RS patients
(r= 0.3, P = 0.07). There were no correlations between WM atrophy
and disease duration at the time of MRI scan in these patients (r =
0.09, P= 0.73 in CBS and r= 0.02, P= 0.9 in RS patients).
Fig. 2. Regions of WM reduction in CBS (A) and RS (B) patients relative to controls. The
most signiﬁcant areas of atrophy observed in 9 CBS patients compared to 16 controls
are the bilateral frontal subcortical WM including the left dominant bilateral precentral
and right cingulate gyrus (A). The most signiﬁcant areas of atrophy observed in
17 RS patients compared to 16 controls are in the bilateral midbrain (B). Signiﬁcance
maps of WM reduction in CBS and RS patients are superimposed on a T1-weighted
brain MRI template image in the Montreal Neurological Institute space. The color
bar represents the t value.
Table 2.
Comparisons of CBS, RS and NC groups showing the locations in which WM reductions were greater in one group than in the other.
Region volume (cluster) t−value Talairach coordinates (x, y, z) Location of local maxima
NC N CBS 973 5.76 −20,−15, 46 left precentral gyrus
1210 5.69 18,−19, 44 right cingulate gyrus
4.81 33,−18, 56 right precentral gyrus
4.57 10, 3, 54 right middle frontal gyrus
NC N RS 2132 6.91 −13,−17,−6 left midbrain
5.21 15,−15,−6 right midbrain
RS N CBS 939 5.27 −18,−18, 42 left cingulate gyrus
4.36 −14,−16, 56 left medial frontal gyrus
911 5.05 29,−36, 51 right postcentral gyrus
4.85 22,−23, 44 right cingulate gyrus
4.59 27,−8, 55 right middle frontal gyrus
CBS N RS 932 4.87 6,−33,−4 right midbrain
4.82 −9,−31,−6 left midbrain
Clusters of WM SPM analysis uncorrected at p b 0.001 with an extent threshold of 300 voxels are shown. The coordinates refer to the Talairach reference space.
Note− CBS = corticobasal syndrome, NC = normal controls, RS = Richardson’s syndrome
Fig. 3. Regions of WM reduction in CBS (A) and RS (B) patients relative to the others.
More atrophic lesions are found in 9 CBS patients than in 17 RS patients, especially
in the bilateral cingulate, right postcentral, and right middle frontal gyrus (A). On the
other hand, signiﬁcant atrophy is observed in the bilateral midbrain in RS patients
(B). Signiﬁcance maps of WM reduction in CBS and RS patients are superimposed on a
T1-weighted brain MRI template image in the Montreal Neurological Institute space.
The color bar represents the t value.
608 K. Sakurai et al. / NeuroImage: Clinical 7 (2015) 605–6104. Discussion
To the best of our knowledge, this is the ﬁrst study to focus on
the diagnostic value of WM volume reduction for discriminating be-
tween clinically diagnosed CBD (i.e., CBS) and PSP (i.e., RS) patients by
VBM using SPM8 plus DARTEL. The present study demonstrated CBS-
speciﬁc left-side dominant asymmetric atrophy in the bilateral frontal
subcortical WM around the precentral gyrus. This asymmetric nature
resulted from the asymmetric symptoms of CBS patients in this study.
The WM abnormality of CBS was consistent with previously reported
neuroradiological and pathological ﬁndings in CBS/CBD (Tokumaru
et al., 2009; Koyama et al., 2007; Doi et al., 1999). Conventional MRI
studies previously revealed asymmetric cerebral atrophy and subcorti-
cal WM T2 prolongation, especially around the central sulcus, with
greater prominence contralateral to the more severely affected side
(Tokumaru et al., 2009; Koyama et al., 2007; Doi et al., 1999). Addition-
ally, advanced techniques including diffusion-weighted and diffusiontensor imaging have also reported the microstructural abnormalities
of cerebral WM including the precentral gyrus, corpus callosum and
corticospinal tract (Erbetta et al., 2009; Rizzo et al., 2008; Boelmans
et al., 2009). Pathological examinations of WM lesions correlated with
the T2 prolongation on MRI have shown the gliosis, demyelination,
and tauopathy associated with CBD (Tokumaru et al., 2009; Doi et al.,
1999). A semiquantitative analysis revealed similar pathological
ﬁndings in the subcortical WM relative to the GM in CBD patients
(Ksiezak-Reding et al., 1994).
Previous VBM studies of CBS/CBD patients mainly evaluated GM
atrophy and focused on frontal lobe atrophy, especially around the
premotor cortex (Boxer et al., 2006; Josephs et al., 2008; Whitwell
et al., 2010; Rohrer et al., 2011; Lee et al., 2011; Whitwell et al., 2011).
On the other hand, the results of this study are consistent with a few
VBM studies, which revealed WM abnormalities including asymmetric
frontal subcortical atrophy, especially around the central sulcus, and
the less severe involvement of the brainstem in CBD patients (Josephs
et al., 2008). However, these studies did not evaluate the diagnostic
Fig. 4. Target VOIs for CBS- and RS-speciﬁc atrophy.The target VOIs of CBS- (A) and RS-
(B) speciﬁc atrophy are determined from the results of VBM analyses, which reveal the
signiﬁcant bilateral frontal subcortical WM atrophy in CBS patients, and the signiﬁcant
midbrain atrophy in RS patients.
Fig. 5. ROC curves for the diagnosis of CBS (A) and RS (B), and differentiation of CBS
from RS by CBS-speciﬁc VOI (C) and RS-speciﬁc VOI (D) using averaged positive Z scores
in target VOIs as a threshold.
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This study demonstrated that the discrimination power of bilateral
frontal WM atrophy was higher than that of midbrain tegmental at-
rophy for differentiating CBS from RS. Considering the pathological
data indicating the signiﬁcantly greater burden of WM abnormalities
in CBD than those in PSP (Forman et al., 2002), it is reasonable to
evaluate subcortical WM abnormalities when diagnosing CBD and
PSP. Abnormal ﬁndings of the cingulate gyrus and corpus callosum
have also been reported in CBS patients (Yamauchi et al., 1998;
Boxer et al., 2006).
If the methodology is only required to discriminate CBS and RS, it is
unnecessary to involve control subjects in the procedure for identifying
diagnostic VOIs. Indeed, their use may result in a ﬁnal test with inferior
ROC characteristics. However, considering the difﬁculty in diagnosing
parkinsonian syndromes, especially atypical PSP, CBD and multiple
system atrophy, it is not always possible for clinicians to narrow down
the differential diagnosis only to “PSP” and/or “CBD” on neurological
examinations. Thus, we think that it is important to evaluate thediagnostic value of the disease-speciﬁc diagnostic VOIs between pa-
tients and normal controls, which may support the imaging diagnosis
of parkinsonian syndromes.
Midbrain tegmental atrophy is one of the well-known imaging ﬁnd-
ings of RS/PSP. Not only conventional MRI studies, but also VBM studies
have reported the utility of this ﬁnding in diagnosing RS/PSP (Boxer
et al., 2006; Josephs et al., 2008; Oba et al., 2005; Agosta et al., 2010;
Massey et al., 2012). On the surface, the result of the present study re-
vealing the poorer utility of this ﬁnding is inconsistent with previous
studies. However, some CBS/CBD patients as well as RS/PSP patients
can have severe midbrain tegmental atrophy (Tokumaru et al., 2009;
Koyama et al., 2007). Clinical symptoms rather than underlying pathol-
ogy have been shown to havemore impact onmidbrain tegmental atro-
phy (Whitwell et al., 2013). Therefore, it is not surprising that the
presence of midbrain tegmental atrophy revealed a lower discrimina-
tion power.
Furthermore, 3D gradient echo imaging enables not only VBM but
also other quantitative evaluations including volume and area mea-
surements, which is useful for diagnosing neurodegenerative diseases
(Oba et al., 2005; Quattrone et al., 2008; Shigemoto et al., 2013). Its
higher spatial resolution is necessary for the detailed evaluation of
various anatomical structures including the midbrain tegmentum,
cerebral peduncle, and superior cerebellar peduncle. However, the
clinical utility of VOI analyses in this study has not been adequately
established, in at least two respects - the group is heterogenous because
the scope of the classiﬁcation is not deﬁned (i.e., severity of symptoms
and staging), and no alternative diagnostic tests are considered. Of
note is that patients’ samples with an unequal size can introduce the
bias in VBM analyses and affect the diagnostic value such as accuracy
and area under ROC curve (Dubey et al., 2014). Furthermore, our
study may have been also limited by the absence of pathological diag-
noses in all cases. In this study, CBS patients were diagnosed according
to formal diagnostic criteria for research purposes (Litvan et al., 2003).
Clinicopathological studies have reported low sensitivity in the ante
mortem diagnosis of CBD (Litvan et al., 1997; Ling et al., 2010), and
pathological studies have suggested that CBD could present with a
broad clinical spectrum including not only CBS, but also non-motor
symptoms including disorders of behavior, executive control, and
language (Lee et al., 2011; Ling et al., 2010). It is also evident that CBS
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including PSP (Ling et al., 2010). Despite the very small number of pa-
tients, pathologically proven CBD patients revealed different patterns
of WM atrophy according to their clinical symptoms (Josephs et al.,
2008). Considering the difﬁculties associated with an ante mortem diag-
nosis of CBD due to the heterogeneity of clinical symptoms and imaging
ﬁndings, more pathologically proven cases of CBD are required to rein-
force the diagnostic value of WM volume reduction on VBM analysis.
5. Conclusions
Our VBM analysis using SPM8 plus DARTEL demonstrated the diag-
nostic value of signiﬁcant atrophy in the bilateral frontal subcortical
WM for diagnosing CBS. Thus, the VBM approach can be useful for
discriminating between CBS and RS. However, considering the broad
clinical spectrum of CBD, more pathologically proven cases of CBD are
required to establish the diagnostic value of WM volume reduction
on VBM analysis.
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